Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

▴ Eisai Logo
For Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma


Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

Tags : #Eisai #Anticanceragent #Denileukin #Diftitox #Genericrecombinant

About the Author


Team Medicircle

Related Stories

07 Sep

JNCASR researchers develop diagnostic therapy for Lung Cancer

Now a safe and cheap way for determining lungs cancer

View
29 Aug

Citriodiol in insect repellent may protect against COVID-19: UK study

Citriodiol had anti-viral properties if mixed with the virus in the liquid phase and on a test surface

View
05 Aug

INST develops new kit to detect fluoride in drinking water

Equipment-free, a simple paper-strip based naked-eye fluoride ion detection and quantification kit in drinking water to evade Fluorosis-based disorders

View
29 Jul

SNBNCBS develops a device for screening of bilirubin level in new born

The operation of the device is based on non-contact and non-invasive spectrometry-based techniques for measurement of neonatal bilirubin level

View
17 Jul

ARCI & Vehant Technologies co-develop UV System for baggage

ARCI & Vehant Technologies co-develop UV System for baggage Scan Disinfection to fight COVID 19

View
15 Jul

Atal Innovation Mission to support Startups with COVID-19 Solutions

9 startups were chosen in the first round for funding

View
26 May

Molecular shock absorbers buffer axonal tension of nerve cells : RRI

Department of Science &Technology along with IISER Pune have proved Spectrin act as ‘shock absorbers’

View
14 May

DST initiatives to protect Divyangjan and Elderly

PSG College of Technology

View
13 Apr

IUSSTF boosts Indo-US virtual networks to address COVID 19 challenges

Collaboration across nations and organizations can leverage and share expertise across S&T communities and facilitate the development of a diverse, globally-engaged science, engineering, and technology-abled workforce, which can proactively work towards solutions for the Pandemic

View
07 Apr

Chandigarh University Uses 3D Printing Technology to Design Splitters That can Bridge Ventilators Shortfall in India

Chandigarh University had constituted a Core Research Group on the call made by Department of Science and Technology (DST) which had invited proposals from companies

View

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025